[Clinical study with piperacillin in the field of obstetrics and gynecology]
Related Experiment Videos
Abstract:
1. Tissue concentrations of piperacillin (PIPC) between 80 to 150 minutes after the completion of 2 g/1 hour dripping infusion were 4.6 approximately 6.4 micrograms/g in the uterus, ovary and oviduct. These concentrations were higher than 80% MIC of the causative organisms, including Staphylococcus aureus, Escherichia coli, Klebsiella, Proteus mirabilis, Bacteroides and Peptococcus, isolated from infections in the field of obstetrics and gynecology. 2. The PIPC concentration in the retroperitoneal space exudate reached a peak value of 34.7 micrograms/ml at 2 hours after the completion of 2 g/1 hour dripping infusion and thereafter maintained a constant level. These concentrations were sufficient for the therapy of parametritis. 3. We administered PIPC at 4 g per day for a period of 4 approximately 8 days to 4 patients with obstetrical and gynecological infectious diseases. All cases proved to respond effectively. No adverse effects and abnormal laboratory findings were observed. From the above, we considered that PIPC was an effective and safe antibiotic against infections in the field of obstetrics and gynecology.
Insights
Piperacillin (PIPC) effectively treats obstetrical and gynecological infections. This antibiotic achieved sufficient tissue concentrations and showed a good safety profile in patients.
Area of Science:
- Pharmacology
- Microbiology
- Obstetrics and Gynecology
Background:
- Antibiotic resistance is a growing concern in obstetrical and gynecological infections.
- Piperacillin (PIPC) is a broad-spectrum antibiotic used to treat various bacterial infections.
Observation:
- PIPC tissue concentrations in the uterus, ovary, and oviduct ranged from 4.6 to 6.4 µg/g.
- PIPC concentrations in retroperitoneal exudate peaked at 34.7 µg/ml, remaining stable.
- Observed concentrations exceeded 80% MIC for common pathogens like Staphylococcus aureus and Escherichia coli.
Findings:
- PIPC demonstrated effective therapeutic concentrations in target tissues and exudates.
- Treatment with PIPC (4 g/day for 4-8 days) in four patients resulted in positive clinical responses.
- No adverse effects or abnormal laboratory findings were reported during PIPC treatment.
Implications:
- PIPC is a potentially effective and safe antibiotic for managing obstetrical and gynecological infections.
- These findings support the use of PIPC in clinical practice for this patient population.
- Further research may explore optimal dosing and duration for specific gynecological infections.